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Summary
Ewing’s sarcoma is associated with a fusion between the EWS and FLI1 genes, forming an EWS/FLI fusion protein. We
developed a system for the identification of cooperative mutations in this tumor through expression of EWS/FLI in primary
human fibroblasts. Gene expression profiling demonstrated that this system recapitulates many features of Ewing’s sar-
coma. EWS/FLI-expressing cells underwent growth arrest, suggesting that growth arrest-abrogating collaborative muta-
tions may be required for tumorigenesis. Expression profiling identified transcriptional upregulation of p53, and the growth
arrest was rescued by inhibition of p53. These data support a role for p53 as a tumor suppressor in Ewing’s sarcoma and
demonstrate the use of transcriptional profiling of model systems in the identification of cooperating mutations in human
cancer.
Introduction human Ewing’s sarcomas, suggesting that the morphology of
the tumor may be governed by the EWS/FLI oncogene itself,
The study of solid tumor formation in pediatrics has made great rather than by the tumor’s cell of origin (Teitell et al., 1999).
strides in recent years by the identification of recurrent chromo- Importantly, other cell types (e.g., Rat-1 fibroblasts, Ncm1, CTR,
somal alterations involved in these tumors (reviewed in Soren- and the NIH 3T3-derived line YAL-7) are not transformable by
sen and Triche, 1996). Ewing’s sarcoma serves as a paradigm EWS/FLI, suggesting that the fusion protein may not be suffi-
for this tumor class, since virtually all Ewing’s sarcomas contain cient for transformation (Arvand et al., 1998, and references
one of a small group of chromosomal translocations (reviewed therein). The full spectrum of EWS/FLI-collaborating mutations,
in Kim and Pelletier, 1999; Kovar, 1998). The most common however, is not known, and the requirements for transformation
translocation is the t(11;22)(q24;q12), which results in a fusion by EWS/FLI in primary cells is poorly understood.
protein containing the amino terminus of the EWS protein joined To address the functional consequences of EWS/FLI in pri-
to the carboxyl terminus of the FLI1 protein, an ETS transcription
mary cells, we report here the establishment of telomerase-
factor (Dellatre et al., 1992). It is believed that the consequence
immortalized human primary fibroblasts conditionally express-of this fusion is to replace the weak transcriptional activation
ing the fusion protein. These cells underwent EWS/FLI-induceddomain of FLI1 with a strong transcriptional activation domain
growth arrest, consistent with the notion that tumorigenesisfrom EWS (Lessnick et al., 1995; May et al., 1993b). The other
requires the acquisition of additional mutations that abrogateEwing’s sarcoma-associated translocations fuse the amino ter-
this growth arrest response. To work toward the elucidationminus of EWS to the DNA binding domain of other ETS family
of this multistep oncogenic process, transcriptional profilingtranscription factors.
coupled with functional validation studies were performed.Although the cell of origin of Ewing’s sarcoma is not known,
These experiments indicated that this growth arrest is p53 de-the transforming potential of EWS/FLI has been demonstrated
pendent, supporting the importance of p53 loss of function inin NIH 3T3 fibroblasts, where it induces colony formation in soft
the pathogenesis of Ewing’s sarcoma and demonstrating theagar and forms tumors when injected in immunodeficient mice
feasibility of this experimental approach to finding cooperative(May et al., 1993a; Teitell et al., 1999). These tumors share the
“small round blue cell” and neural differentiation properties of mutations in cancer.
S I G N I F I C A N C E
Cancer arises as a consequence of multiple cooperating genetic events. The unique character and early age of onset of pediatric
tumors suggests that there may be qualitative and/or quantitative differences in the alterations required as compared to adult
tumors, but this has not been systematically evaluated. Such an evaluation has been hampered by the difficulty in identification of
cooperative mutations involved in these tumors. We developed a system to identify cooperative mutations in the pediatric tumor
Ewing’s sarcoma. We describe a generalizable approach to the validation of this experimental system using microarray-based
transcriptional profiling of primary patient samples. The utility of this approach is demonstrated by the identification and functional
validation of p53 as a tumor suppressor in Ewing’s sarcoma.
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Figure 1. Growth phenotype of tet-EF cells
A: Tet-EF cells expressed EWS/FLI (as detected by Western blot with anti-FLAG antibody) following removal of doxycycline from the culture media. Tet-ctrl
cells do not contain an inducible cDNA. Tubulin staining demonstrates equal loading of samples. B: The growth of tet-EF cells was significantly repressed
by the presence of EWS/FLI expression (i.e., without doxycycline; open circles) as compared to the absence of EWS/FLI expression (i.e., with doxycycline;
closed circles). The optical density at 595 nm (OD 595) is proportional to the cell number at each time point. Error bars indicate the standard deviations
of triplicate samples. C: Cell cycle analysis of tet-EF cells reveals a decrease in the S phase percentage from 24.4% to 15.7% when EWS/FLI is expressed
(i.e., without doxycycline). D: SA--gal staining of tet-EF cells does not demonstrate significant differences in the presence or absence of doxycycline.
Although the total number of cells is decreased in the induced tet-EF sample (dox) as compared to the uninduced tet-EF cell sample (dox), the absolute
number of cells staining positively for SA--gal is identical between the two. A senescent positive control (tet-ctrl cells expressing SV40 small T antigen) is
shown for comparison. E: The growth arrest of tet-EF cells is reversible, as demonstrated by resumption of growth when EWS/FLI expression was inhibited by
the readdition of doxycycline to the growth media. The standard deviations from triplicate samples are represented by error bars.
Results response, such as that seen with c-myc expression in nontrans-
formed fibroblasts (reviewed in Prendergast, 1999). In situ stain-
ing with FITC-VAD-fmk, gel electrophoresis to detect genomicGrowth phenotype of inducible EWS/FLI
To study the biological effects of EWS/FLI in primary human DNA laddering, DAPI staining of nuclei to detect characteristic
nuclear condensation, and annexin V staining, a hallmark ofcells, human neonatal foreskin fibroblasts were infected with a
retrovirus harboring the human telomerase (hTERT) cDNA to apoptosis, similarly failed to demonstrate an apoptotic response
to EWS/FLI expression (data not shown). Additionally, in con-provide for an extended life span without karyotypic abnormali-
ties. These cells were then engineered to express EWS/FLI trast to the effects of RAS expression in primary cells (Serrano
et al., 1997), EWS/FLI did not induce a senescent phenotype,under the control of a tetracycline-repressible element and were
designated tet-EF cells (Figure 1A). A control cell line (tet-ctrl as demonstrated by the absence of the typical morphologic
changes of cellular senescence and the absence of senescence-cells) lacking the EWS/FLI cDNA was similarly generated.
Growth curves were generated using tet-EF and tet-ctrl cells associated -galactosidase activity (Figure 1D). Furthermore,
the EWS/FLI-induced growth arrest was completely reversedfollowing the withdrawal of doxycycline (Figure 1B). Control cells
grew similarly in the presence or absence of doxycycline. In by the readdition of doxycycline, thereby repressing EWS/FLI
expression (Figure 1E). Taken together, these results indicatecontrast, tet-EF cells exhibited a dramatic inhibition of popula-
tion growth when induced to express EWS/FLI. An independent that EWS/FLI induces a reversible, nonsenescent, nonapoptotic
growth arrest in primary cells.EWS/FLI-inducible clone demonstrated an identical growth-
suppressive response to EWS/FLI (data not shown).
Cell cycle analysis of tet-EF cells demonstrated a decrease Validation of tet-EF model
The growth arrest induced by EWS/FLI is consistent with thein S phase following induction of EWS/FLI (Figure 1C). There
was no evidence of a sub-G0 population to suggest an apoptotic hypothesis that additional mutations are required to abrogate
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this default growth arrest pathway before Ewing’s tumors could Many of the genes downregulated by EWS/FLI are involved
in cell cycle progression and DNA replication, including multipleform. One potential concern, however, is that the tet-EF fibro-
cyclins (CCNA2, CCNB1, CCNE1, and CCNE2), a cyclin-depen-blast system might not reflect the biology of naturally occurring
dent kinase (CDC2), DNA polymerase subunits (POLA, POL2A,Ewing’s sarcoma. To address this, we compared tet-EF cells
POLE2, and PCNA), replication factor subunits (RFC2, RFC3,to Ewing’s sarcoma cell lines and tumor samples.
RFC4, and RFC5), DNA primase subunits (PRIM1 and PRIM2A),Western blot analysis showed that the expression of EWS/
and the Ki-67 antigen (MKI67). This transcriptional readout isFLI protein is similar in tet-EF cells as compared to cell lines
consistent with the cell cycle arrest that ensues following EWS/derived from Ewing’s sarcoma patient samples (Figure 2A).
FLI expression.Given this comparable level of expression, it is unlikely that the
Among EWS/FLI upregulated genes were frizzled-1 (FZD1),growth arrest observed in EWS/FLI-expressing tet-EF cells is
FRAT2 (a GSK binding protein), and MYC, suggesting that mod-simply a result of overexpression of the fusion protein.
ulation of the WNT signaling pathway may be occurring in theseTet-EF cells induced to express EWS/FLI were next analyzed
cells, and consistent with the observation of elevated levels ofon DNA microarrays containing probes for approximately
c-MYC in Ewing’s sarcoma (McKeon et al., 1988). Upregulation12,600 named genes and expressed-sequence tags (see
of the PDGF-receptor- (PDGFRB), the PI-3-kinase p85 subunitSupplementary Information at http://www.genome.wi.mit.edu/
(PIK3R1), and multiple MAP-kinase pathway genes (such ascancer/Ewings). Among the genes induced by EWS/FLI in these
MAPK10, MAP2K5, and MAPKAPK2) suggests that EWS/FLIexperiments was MIC2, a marker of Ewing’s sarcoma used in
may modulate multiple points in receptor tyrosine-kinase path-routine clinical practice (Figure 2B; Ambros et al., 1991; Fellinger
ways. Interestingly, induction of VEGF expression by EWS/FLIet al., 1991). This result supports the validity of the cell culture
suggests a possible mechanism for the extensive tumor angio-system for the study of EWS/FLI.
genesis observed in Ewing’s sarcoma. An additional group ofTo further explore the validity of this model system, we
EWS/FLI-induced genes include p53 (TP53), FAS/APOcompared the list of EWS/FLI-induced genes to the gene ex-
(TNFRSF6), CDKN1C, TGFB1, and TIMP3—all of which are as-pression profiles of Ewing’s sarcoma patient samples. The
sociated with tumor growth inhibition. We hypothesized that12,600 gene oligonucleotide microarray data generated herein
these genes represent cell-autonomous tumor-suppressive re-were compared to the 2308 gene cDNA microarray data of Khan
sponses to oncogenic stress. One implication of this hypothesiset al., which represent 63 small round blue cell tumors and cell
is that Ewing’s sarcoma tumor cells have bypassed these cellu-lines, including 23 Ewing’s sarcomas, 8 Burkitt’s lymphomas,
lar responses to allow for unrestricted cell growth. As described12 neuroblastomas, and 20 rhabdomyosarcomas (Khan et al.,
below, the plausibility of this hypothesis was functionally vali-2001). Permutation testing of the oligonucleotide array data
dated for one of these genes—p53.revealed that 117 probes were reproducibly induced by EWS/
FLI in tet-EF cells (p  0.01; Figure 2C). Analysis of the patient
EWS/FLI induction of p53samples identified 686 probes that were statistically significant
p53 represents an attractive candidate to explain EWS/FLI-markers of Ewing’s sarcoma (p  0.01; Figure 2C). Strikingly,
mediated growth arrest, since p53 transcript levels were more54 (46.2%) of the 117 genes that were induced by the EWS/
highly correlated with EWS/FLI expression than any of the otherFLI fusion in tet-EF cells were also Ewing’s-specific markers,
12,600 genes on the array, and increases in p53 function arefar beyond what would have been expected by chance alone
thought to be central to the growth arrest and increased cell(p  0.0001; Figure 2D). We similarly identified genes that were
death observed in primary cells expressing oncogenes (Serranospecific to Burkitt’s lymphoma, neuroblastoma, and rhabdo-
et al., 1997; Zindy et al., 1998). Quantitative, real-time PCR
myosarcoma, and compared these to the EWS/FLI-induced
experiments showed induction of p53 mRNA levels that were
genes in tet-EF cells (Figures 2C and 2D). No significant molecu- consistent with the microarray findings (Figure 3B). Western blot
lar similarity between the tet-EF cells and these other tumor analysis further demonstrated significant increases in p53 levels
types was observed (Figure 2D). These results demonstrate that following EWS/FLI induction (Figure 4A). Similar increases in
tet-EF cells have molecular features that are similar to Ewing’s the p53 target p21 support the notion that the increase in p53
sarcoma, and thus they confirm the suitability of tet-EF cells as levels was functionally significant (see Figure 4C).
a model of Ewing’s sarcoma. Oncogene expression in primary murine fibroblasts often
activate the p53 tumor suppressor via increases in the p19ARF
Molecular consequence of EWS/FLI expression protein (p14ARF in human cells), which results in increased
We next explored the mechanism by which EWS/FLI induces stability of p53 and accumulation of active protein (Bates et al.,
growth arrest, reasoning that genes involved in that process 1998; Damalas et al., 2001; de Stanchina et al., 1998; Palmero
would be candidates for collaborating mutations in Ewing’s tu- et al., 1998; Pomerantz et al., 1998; Zhang et al., 1998; Zindy et
morigenesis. For this purpose, we turned again to the gene al., 1998). Posttranslational regulation of p53 levels are similarly
expression consequences of EWS/FLI induction in tet-EF cells. observed in MDM2-overexpressing cells (Haupt et al., 1997;
EWS/FLI-regulated genes were clustered using self-organizing Kubbutat et al., 1997). The observed increases in p53 mRNA
maps (SOM) in order to capture the predominant patterns of levels in tet-EF cells, however, raised the possibility that the
gene expression (Figure 3A; Tamayo et al., 1999). The data regulation of p53 in this system may occur transcriptionally. In
could be divided into three major groups: those that were down- support of this, we observed no increase in p14ARF protein
regulated in response to EWS/FLI (cluster 0; 347 genes), those levels in response to EWS/FLI expression and minimal change
that were upregulated (cluster 2; 214 genes), and those that in MDM2 protein levels (Figure 4A). Quantitative, real-time PCR
had more variable expression patterns (cluster 1; 134 genes). experiments demonstrated no increase in p14ARF mRNA levels
A complete list of these genes can be found in Supplemental and, in fact, demonstrated 3-fold decrease in mRNA levels, in
good agreement with the Western blot data (data not shown).Information at http://www.genome.wi.mit.edu/cancer/Ewings.
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Figure 2. Tet-EF cells have molecular features
that are similar to Ewing’s sarcoma
A: Western blot analysis using an anti-FLI-1 anti-
body demonstrates that the level of EWS/FLI ex-
pressed in the absence of doxycycline is similar
to the levels of EWS/FLI protein expressed by the
Ewing’s sarcoma cell lines A673, SK-N-MC, RD-
ES-1, and EWS-502. Tubulin is shown as a loading
control. B: Microarray-detected MIC2 mRNA ex-
pression levels increase following EWS/FLI expres-
sion. C: The oligonucleotide microarray data for
tet-EF cells expressing EWS/FLI were compared
to the publicly-available cDNA microarray ex-
pression data for pediatric small round cell tu-
mors (SRCT) (Khan et al., 2001), including Ewing’s
sarcoma, Burkitt’s lymphoma (BL), neuroblas-
toma (NBL), and rhabdomyosarcoma (RMS). Oli-
gonucleotide probes and cDNAs were first
mapped to their Unigene clusters, and clusters
that were present on both microarray platforms
were identified. Data from the common clusters
were used for the subsequent analysis. The differ-
ent numbers of probes/cDNAs obtained for
each data set is a result of different amounts of
redundancy present on each platform. K-near-
est neighbor (Knn) analysis and permutation test-
ing was used to identify those genes that in-
crease following EWS/FLI expression in tet-EF cells
(left; n  117 at 99% significance level). A repre-
sentative experiment is shown. Each column rep-
resents the day following induction of EWS/FLI.
Each row represents a different gene. The same
method was used to identify marker genes that
are more highly expressed in each SRCT type
than expected by chance alone (right; the top
50 genes are shown for each tumor type). For
both panels, expression levels are normalized
such that the mean is 0 and the standard devia-
tion is 1. Expression levels above the mean are
red, and those below the mean are blue. D: EWS/
FLI-regulated genes are more overlapping with
Ewing’s sarcoma markers than would be ex-
pected by chance alone (p  0.0001). For each
tumor type shown, the number of probes that
pass permutation testing at the 99% significance
level is shown. Chi-square analysis was used to
generate the p values.
Finally, pulse-chase experiments demonstrated that p53 half- vated in response to EWS/FLI expression. Thus, EWS/FLI ex-
pression results in increased p53 levels because of transcrip-life was not prolonged following EWS/FLI induction (Figure 4B).
Importantly, introduction of p14ARF or p53 expression by ret- tional upregulation, rather than posttranslational mechanisms.
roviral transduction led to the anticipated increases in both
MDM2 and p53 levels (Figure 4A; Stott et al., 1998). Taken Growth arrest is p53 dependent
We next determined whether p53 induction was critical for thetogether, these results demonstrate that tet-EF cells carry a
functional ARF-MDM2-p53 axis, but this pathway is not acti- observed growth arrest phenotype following EWS/FLI induction.
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Figure 3. EWS/FLI upregulates p53 transcription
A: Self-organized map analysis of tet-EF cells expressing EWS/FLI. The tet-EF
cell microarray data was initially filtered to limit the data set to those genes
that demonstrated at least 2.5-fold changes in two or more time points as
compared to day 0. Genes were then grouped into three clusters (a 3 
1 SOM). The mean expression level of each clustered time point is repre-
sented in blue, and the standard deviations are in red. Independent dupli- Figure 4. EWS/FLI increases p53 protein levels
cate EWS/FLI inductions in tet-EF cells are represented, and the day of A: Western blot analysis of the p53 pathway in tet-EF cells following 3 days
induction of each point is indicated. Cluster 0 (c0) represents downregu- of induced EWS/FLI expression. EWS/FLI expression results in increased p53
lated genes, cluster 2 (c2) represents upregulated genes, and cluster 1 (c1) protein levels without increased p14ARF levels or significant alterations in
represents genes with intermediate/indeterminate patterns. B: Quantitative MDM2 levels. Infection of tet-EF cells with a p14ARF retrovirus demonstrates
real-time PCR (qRT-PCR) of an independent sample of tet-EF cells expressing that p14ARF is able to mediate increased p53 levels. Increased MDM2 levels
EWS/FLI demonstrates similar increase in p53 mRNA as compared to the are observed following infection of either p14ARF or p53 retroviruses, as has
microarray analysis. The p53 mRNA expression level from the microarray is been previously reported (Stott et al., 1998, and references therein). Tubulin
plotted on the left, and the levels as determined by qRT-PCR is shown on is shown as a loading control. B: Pulse-chase analysis of p53 protein stability
the right. The microarray data represents the mean of both runs with the in the presence of EWS/FLI expression (open circles, without doxycycline)
standard deviations indicated. The qRT-PCR analysis was performed on a or in the absence of EWS/FLI expression (closed circles, with doxycycline).
single independent sample pair. Relative p53 quantities (as determined using a phosphor imager) are shown
plotted against time (on a logarithmic scale). C: Western blot analysis of
tet-EF/E6 cells and tet-EF/zeo control cells following 3 days of induced EWS/
FLI expression. Increases in p53 and p21 following EWS/FLI expression are
abrogated by coexpression of E6 protein. Tubulin is shown as a loadingWe utilized the E6 protein of human papillomavirus HPV16 as control.
an inhibitor of p53 (Vousden, 1993). Polyclonal populations of
tet-EF cells stably expressing E6 (tet-EF/E6 cells) were gener-
ated by retroviral gene transfer. Control cells lacking E6 (tet-
Multistep process of transformationEF/zeo) were similarly derived.
We next asked whether inhibition of p53 was sufficient for EWS/E6 expression in tet-EF cells led to expected diminution of
FLI-mediated transformation. Tet-EF/E6 cells were plated in softbasal p53 protein levels and was able to completely inhibit
agar in the presence and absence of doxycycline. No coloniesincreased p53 levels seen with EWS/FLI induction (Figure 4C).
formed when tet-EF/E6 cells were induced to express EWS/FLIAdditionally, increases in p21 were also inhibited by the pres-
protein (Figure 5B). Importantly, these cells do become trans-ence of the E6 protein (Figure 4C). Importantly, EWS/FLI expres-
formed through coexpression of HPV E6 and E7, SV40 small T
sion levels were similar in the two cell types (Figure 4C).
antigen, and RASV12 (Figure 5B; Hahn et al., 2002). Interestingly,
The growth characteristics of tet-EF/E6 cells are shown (Fig- the colony-forming potential of these cells is inhibited by expres-
ure 5A). Whereas tet-EF/zeo cells undergo growth arrest in re- sion of EWS/FLI, suggesting that additional tumor-suppressive
sponse to EWS/FLI induction, this growth arrest was completely pathways may be operative in these cells. To examine this possi-
abrogated by E6 expression. A dominant-negative allele of p53 bility, 3T5 growth assays were performed with tet-EF/E6 cells.
demonstrated a similar bypass in the growth arrest response Whereas E6 blocked an early, p53-dependent growth arrest,
to EWS/FLI (see below). These experiments indicate that p53 subsequent p53-independent growth inhibition was then en-
countered (Figure 5C). A dominant-negative allele of p53,is a critical mediator of EWS/FLI growth arrest.
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Figure 5. EWS/FLI-mediated growth arrest is p53
dependent
A: Growth curve analysis of tet-EF/E6 cells and
tet-EF/zeo cells demonstrates bypass of growth
arrest in the presence of E6 protein. The optical
density at 595 nm is proportional to the cell num-
ber at each time point. Error bars demonstrate
the standard deviation of triplicate samples. B:
Soft agar assays demonstrate that EWS/FLI ex-
pression does not result in colony formation in
the presence of E6 protein. Tet-EF/E6E7/ST/RASV12
cells utilized as a positive control (in the presence
of doxycycline) demonstrate that colony forma-
tion is suppressed by EWS/FLI expression (in the
absence of doxycycline). Tet-ctrl/E6E7/ST/RASV12
cells form colonies in the presence and absence
of doxycycline. Photomicrographs were taken 3
weeks following plating. The plus and minus signs
indicate the qualitative level of transformation.
C: Passage on a 3T5 schedule reveals that while
tet-EF/E6 cells bypass an early growth arrest, they
undergo a secondary arrest after two passages.
Tet-EF/zeo cells are shown for comparison. Tet-
EF/p53DD cells demonstrate a similar pattern of
delayed growth arrest to the tet-EF/E6 cells, thus
proving that the effects of E6 are mediated by
p53 inhibition, rather than a non-p53-mediated
function of E6.
p53DD (Shaulian et al., 1992), similarly abrogated the growth Activation of tumor suppressor pathways by oncogenic
stress is an emerging theme. RAS, MYC, E1A, E2F1, andarrest phenotype, suggesting that the effects observed with
HPV E6 are a result of its p53-inhibitory functions, rather than its -catenin (CTNNB1) all induce p53-dependent growth-inhibi-
tory responses when expressed in primary murine cells (Batesp53-independent activities. Taken together, these data suggest
that the pathogenesis of Ewing’s sarcoma requires not only et al., 1998; Damalas et al., 2001; de Stanchina et al., 1998;
Palmero et al., 1998; Zindy et al., 1998). In each of these in-abrogation of the p53 pathway, but also requires mutations in
genes leading to the abrogation of an additional, as yet unchar- stances, upregulation of p53 protein levels is thought to be
mediated by the ARF-MDM2-p53 axis. Indeed, expression ofacterized growth-suppressive pathway.
EWS/FLI in primary murine fibroblasts results in a growth arrest
with apoptosis that can be circumvented by loss of eitherDiscussion
p19ARF or p53 (Deneen and Denny, 2001). Importantly, we did
not observe activation of the ARF-MDM2 pathway in primaryWe have demonstrated the potential for deciphering the
human fibroblasts, suggesting that regulation of the p53 tumormultistep pathogenesis of Ewing’s sarcoma by integrating tran-
suppressor may be different in different organisms. Consistentscriptional profiling data from model systems and patient tumor
samples with functional assays in model systems. We identified with this notion, recent work from Sedivy and coworkers has
demonstrated that p53 induction by RAS in primary humanp53 as a potential tumor suppressor in Ewing’s sarcoma through
this method. A role for p53 alterations in Ewing’s sarcoma is fibroblasts also occurs in an ARF-independent fashion (Wei et
al., 2001). Thus, it would appear that regulation of p53 levelssupported by the clinical literature, and thus lends validity to
this approach. Mutations in p53 have been detected in 5%–20% by oncogenic stress in primary human cells utilizes different
upstream components than those used in murine cells. In theof Ewing’s sarcoma tumor samples (Kovar et al., 1993; Patino-
Garcia and Sierrasesumaga, 1997). Amplification of MDM2 and case of EWS/FLI, transcriptional upregulation of p53 seems to
be the predominant mode of regulation. Additional work will bedeletions of the CDKN2A locus (encoding overlapping INK4A
and ARF transcripts) have also been described in Ewing’s sar- required to determine whether this finding is specific for EWS/
FLI, or whether it is a more generalized phenomenon. As manycoma (e.g., Kovar et al., 1997; Ladanyi et al., 1995). Thus, alter-
ations in the p53 pathway may be relatively frequent in this cases of Ewing’s sarcoma have no evidence of mutation of the
p53 pathway, abrogation of the transcriptional induction of p53tumor.
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Ewing’s sarcoma cell lines A673, SK-N-MC, and RD-ES-1 were obtainedby EWS/FLI represents a potential mechanism of escaping p53-
from American Type Culture Collection (ATCC) and grown according tomediated growth control.
ATCC recommendations. The Ewing’s sarcoma cell line EWS-502 was grownWhile HPV16 E6 effectively rescued the early EWS/FLI-
in 15% FCS in RPMI media.
induced growth arrest, a subsequent p53-independent growth
arrest was encountered, suggesting that still additional muta- Immunodetection
tions must be acquired in the process of Ewing’s sarcoma The following antibodies were used: M2-anti-FLAG (Stratagene or Sigma);
anti-FLI-1 (BD PharMingen 554266); anti-p14ARF (Oncogene Researchpathogenesis. Of note, the delayed growth-inhibitory response
Products NA70); anti-MDM2 (Oncogene Research Products OP46); anti-p53to EWS/FLI was dominant over not only E6, but also the combi-
(DO-1; Santa Cruz sc-126); anti-p21 (Santa Cruz sc-397); and anti--tubulinnation of E6E7, ST, and RAS (and therefore, the transformed
(Santa Cruz sc-5286).
phenotype). The transcriptional data provided in this study may
allow for the identification of additional genetic alterations re- Growth curves
quired for Ewing’s sarcoma development. A number of growth- In triplicate, 2  104–3  104 cells were plated per well of 12-well plates in
media containing tetracycline. On day 0, the cells were induced to expressinhibitory genes were upregulated following EWS/FLI induction
EWS/FLI. Uninduced cells were refed with media containing 1 g/ml ofin tet-EF cells. Further studies, such as those described in this
doxycycline. At the indicated times, the cells were washed, fixed, and stainedreport, may provide evidence for functional roles of these in
(Serrano et al., 1997).
the growth arrest of tet-EF cells expressing EWS/FLI and, by
inference, for the role of these in the development of Ewing’s Cell cycle analysis
sarcoma. Three days after EWS/FLI induction, cells were fixed in 35% ethanol, washed
in PBS, and resuspended in PBS containing propidium iodide and RNaseIt has been recently suggested that loss of the p16-RB
A. Cells were subsequently analyzed by flow cytometry.pathway allows for stable EWS/FLI expression in primary fibro-
blasts, suggesting that abrogation of the RB pathway may coop-
Microarray analysiserate with EWS/FLI (Deneen and Denny, 2001). In our human
Tet-EF cells were plated at 1  106 cells per 15 cm plate, five plates in total,
model system, however, RB blockade with HPV E7 did not in tetracycline-containing media. On day 0, one plate of cells was collected,
abrogate EWS/FLI-mediated growth arrest, nor were we able pelleted, and stored frozen in Trizol reagent (Life Technologies). The re-
to detect upregulation of p16INK4a protein following EWS/FLI maining plates were induced to express EWS/FLI as described above, and
each day one plate was collected, pelleted, and stored frozen in Trizol. Theexpression in our model system (S.L.L. and T.R.G., unpublished
entire induction experiment was repeated on a subsequent week. Followingobservations). Thus, the p16-RB pathway is not a critical media-
collection of the final sample, total RNA was isolated, processed, hybridizedtor of EWS/FLI growth arrest in tet-EF cells. It seems likely that
to Affymetrix U95Av2 microarrays, and scanned. The expression value for
different cellular backgrounds may emphasize different growth- each gene was calculated using Affymetrix GeneChip software. Minor differ-
suppressive pathways and may thus be exploited to gain a more ences in microarray intensity were corrected using a linear scaling method
complete understanding of Ewing’s sarcoma genesis. as detailed in the supplemental section. K-nearest neighbor (Knn) analysis
and SOMs were performed using our GeneCluster software package avail-
Experimental procedures able at http://www-genome.wi.mit.edu/cancer/software/software (Golub
et al., 1999; Tamayo et al., 1999). Complete data sets, in-depth description
Constructs and retroviruses of the analysis, and supplemental materials are available at http://www.
The human telomerase (hTERT) cDNA was cloned into the pWZL-blast	 genome.wi.mit.edu/cancer/Ewings.
vector, which directs blasticidin resistance. HPV16 E6 and E6E7 cDNAs
were PCR amplified from an HPV16 genomic plasmid and cloned into pWZL- Real-time quantitative PCR
zeo	 vector. FLAG-epitope-tagged EWS/FLI was subcloned into the pREV- Three days after EWS/FLI induction in tet-EF cells, total cellular RNA was
TRE vector (Clontech). The cDNAs for p14ARF and wild-type p53 were prepared and was treated with RNase-free DNase I (Promega). Reactions
subcloned into the MSCV-puro vector (Clontech) for retroviral production were prepared using TaqMan One-Step RT-PCR reagents from Applied
and into the pBluescript II KS vector (Stratagene) for in vitro transcription Biosystems. One-step RT-PCR consisted of an initial incubation at 48
C for
reactions. The cDNA for p53DD was subcloned into the pBabe-puro vector 30 min, followed by a denaturation step at 95
C for 10 min and amplification
(Morgenstern and Land, 1990). for 40 cycles of 15 s at 95
C and 1 min at 60
C. For each case, 200 ng of total
Vesicular stomatitis virus-G glycoprotein pseudotyped retroviruses were RNA was analyzed. Each experiment included three nontemplate controls to
prepared by transient cotransfection of retroviral vectors with packaging detect any template contamination; a control lacking reverse transcriptase
plasmids in either 293-EBNA (Invitrogen) or 293T cells. Infection of target was included for each sample to detect any residual genomic DNA. Standard
cells was carried out in the presence of 8 g/ml polybrene. curves were constructed by serial 10-fold dilutions from 107 to 103 copies
of in vitro transcribed RNA of each gene to be quantified. The reproducibility
Cell culture of the quantitative measurements was evaluated by conducting triplicate
Primary fibroblasts were prepared from discarded neonatal foreskins and PCR assessments. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were immortalized by infection with hTERT-pWZL-blast	 retrovirus and se- mRNA expression was analyzed for each sample in parallel wells to assess
lection with blasticidin (Invitrogen) at population doubling 20. Tet-EF cells the integrity of the RNA. Primers and probes were obtained from Integrated
were generated by retroviral transduction of pREV-TETOFF (Clontech). Fol- DNA Technologies as follows: p53for, 5-GCCAAAGAAGAAACCACTGG
lowing neomycin selection, a portion of the surviving population was infected ATG-3; p53rev, 5-TGAGTTCCAAGGCCTCATTCAG-3; p53probe, 5-FAM-
with FLAG-EWS/FLI-pREV-TRE retrovirus and subjected to hygromycin se- ATTTCACCCTTCAGATCCGTGGGCGT-TAMRA-3; p14ARFfor, 5-TGATG
lection in the presence of tetracycline. Negative control cells were prepared CTACTGAGGAGCCAGC-3; p14ARFrev, 5-ACCACCAGCGTGTCCAGGAA-3;
by introducing an empty pREV-TRE retroviral construct instead of the EWS/ p14ARFprobe, 5-FAM-ACTCTCACCCGACCCGTGCACGACGCTGC-TA
FLI-containing construct. Cells were maintained in 10%FCS in DMEM sup- MRA-3; GAPDHfor, 5-GAAGGTGAAGGTCGGAGT-3, GAPDHrev, 5-GAA
plemented with 1 g/ml doxycycline or tetracycline, 300 g/ml G418, and GATGGTGATGGGATTTC-3; and GAPDHprobe, 5-VIC-CAAGCTTCCCGT
TCTCAGCC-TAMRA-3.100 g/ml hygromycin.
Induction of EWS/FLI was accomplished by plating the cells in media
containing 1 g/ml tetracycline the day before induction, washing the tet- Pulse-chase analysis of p53
EF cells three times with phosphate-buffered saline (PBS) on the day of Tet-EF cells were plated in 6 cm plates in the presence or absence of
doxycycline 3 days prior to analysis. Cells were then preincubated for 1 hrinduction, and refeeding with tetracycline-free growth media.
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Fellinger, E.J., Garin-Chesa, P., Triche, T.J., Huvos, A.G., and Rettig, W.J.in methionine/cysteine-free media (with dialyzed FCS) and pulsed with 400
(1991). Immunohistochemical analysis of Ewing’s sarcoma cell surface anti-Ci/ml of methionine/cysteine (Tran35S-Label, ICN Biomedicals) for 1 hr.
gen p30/32MIC2. Am. J. Pathol. 139, 317–325.Cells were washed and chased with full media containing 2 mM methionine/
2 mM cysteine for the indicated times. Cells were then washed with PBS Golub, T.R., Slonim, D.K., Tamayo, P., Huard, C., Gaasenbeek, M., Mesirov,
and lysed in 1 ml RIPA buffer containing protease inhibitors. The entire J.P., Coller, H., Loh, M.L., Downing, J.R., Caligiuri, M.A., et al. (1999). Molecu-
quantity of lysate was precleared, subjected to immunoprecipitation with lar classification of cancer: class discovery and class prediction by gene
anti-p53-conjugated beads (DO-1; Santa Cruz sc-126 AC), and resolved by expression monitoring. Science 286, 531–537.
electrophoresis. Relative p53 levels were determined by phosphor imaging.
Hahn, W.C., Dessain, S.K., Brooks, M.W., King, J.E., Elenbaas, B., Sabatini,Relative labeling of the lysates was determined by electrophoresis of 1 l
D.M., DeCaprio, J.A., and Weinberg, R.A. (2002). Enumeration of the simiantotal lysate (before immunoprecipitation) and phosphor imager analysis. The
virus 40 early region elements necessary for human cell transformation. Mol.raw p53 values obtained were corrected for differences in specific labeling
Cell. Biol. 22, 2111–2123.between the samples.
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Cells were seeded at a density of 1  105 per 6 cm plate in 0.35% agar in
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